Food and Drug Administration

Drug Safety and Risk Management Advisory Committee (DSaRM)

Slides

THURSDAY FEBRUARY 9, 2006

Overview of Attention Deficit Hyperactivity Disorder (ADHD) and its Pharmacotherapy [HTML] [PPT]	Andrew Mosholder, M.D., M.P.H. Division of Drug Risk Evaluation, Office of Drug Safety (ODS)
Studying Cardiovascular Risk with Drug Treatments of ADHD [HTML] [PPT]	Kate Gelperin, M.D., M.P.H. Division of Drug Risk Evaluation, ODS
ADHD Drugs and Cardiovascular Outcomes: Preliminary Feasibility Study Results [HTML] [PPT]	David Graham, M.D., M.P.H. Associate Director for Science and Medicine, ODS
Challenges of Studying Cardiovascular Outcomes in ADHD [HTML] [PPT]	Elizabeth Andrews, M.P.H., Ph.D. Vice President, Pharmacoepidemiology and Risk Management, Research Triangle Institute Health Solutions
Open Public Hearing Speakers [PPT]
	A. J. Allen, M.D., Ph.D. Global Medical Director-Strattera Eli Lilly and Company HTML PPT
	M. Christopher Griffith, M.D. Children and Adults with Attention Deficit Hyperactivity Disorder (CHADD) HTML PPT
Introduction of Questions [HTML] [PPT]	Gerald Dal Pan, M.D., M.H.S. Director, ODS